SUBSCRIBE
SUBSCRIBE

Novo Nordisk A/S’s Hemophilia Drug, NovoSeven Can Damage Heart, Study Finds

November 4, 2010 | 
1 min read

BOSTON, Nov 3 (Reuters) - Using high doses of Novo Nordisk’s (NOVOb.CO) anti-clotting medicine to treat dangerous bleeding in non-hemophiliacs may raise the risk of heart attack or related complications, researchers said on Wednesday.

Europe
Novo Nordisk
MORE ON THIS TOPIC
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Mergers & acquisitions
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
December 9, 2024
 · 
2 min read
 · 
Tristan Manalac
Facade of Novo Nordisk's office in Fremont, California
Manufacturing
Novo Continues Manufacturing Spending Spree With $400M Denmark Expansion, $200M Plant Purchase
December 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Sanofi's Distribution Center in Quebec, Canada
Radiopharmaceuticals
Sanofi Inks $326M Radiopharma Deal With Orano
October 17, 2024
 · 
2 min read
 · 
Tristan Manalac